NELSON: the Trafalgar of lung cancer screening?

Symposium
Chairs: J. van Meerbeeck (Edegem (Antwerp), Belgium), M. Revel (Paris, France)
Aims: to present NELSON results 1 year after the first data were released, consensus data on participant selection and consensus data on nodule handling to minimise the false positive rate; to discuss the cost-effectiveness of lung cancer screening; to address the ethical dilemma of screening current smokers.

Update on NELSON including its cost-effectiveness analysis H. De Koning (Rotterdam, Netherlands)
Screening for lung cancer: who should (not) be enrolled? C. Thomson (Boston, United States of America)
(Not) screening smokers: a patient’s view J. Rawlinson (Tipton, United Kingdom)
How do we handle nodules to minimise the false positive rate? D. Baldwin (Nottingham (Nottinghamshire), United Kingdom)
Introduction on the ESR/ERS statement on low-dose lung cancer screening H. Kauczor (Heidelberg, Germany)